Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating

Published 11/08/2025, 11:36
Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating

Investing.com - Stifel has resumed coverage of Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and set a price target of $89.00, according to a research note released Monday. The stock, currently trading near its 52-week high of $61.00, has shown remarkable momentum with a 45% gain year-to-date. InvestingPro data reveals that 5 analysts have recently revised their earnings estimates upward for the upcoming period.

The research firm highlighted Mirum’s "cash-flow positive, high-growth commercial business" and its mid- to late-stage pipeline with multiple growth opportunities, including a pivotal catalyst expected in the second quarter of 2026 for primary sclerosing cholangitis (PSC). This assessment aligns with the company’s impressive 62.3% revenue growth over the last twelve months, according to InvestingPro data.

Stifel expressed optimism about growth prospects for Livmarli, citing multiple "upside-levers" including organic growth in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), weight-based pricing, and the EXPAND program, alongside steady revenue from Ctexli and Cholbam.

The firm also conveyed "strong conviction" in volixibat ahead of pivotal PSC/primary biliary cholangitis (PBC) data, projecting it as a potential blockbuster opportunity even with conservative assumptions.

Stifel noted that Mirum’s strong financial position, growing commercial business, pipeline optionality, and management team make it stand out "in what remains a discerning biotech tape," despite the stock’s recent strong performance.

In other recent news, Mirum Pharmaceuticals reported strong second-quarter 2025 financial results, with total revenues reaching $127.8 million. This marks a significant 64% increase compared to the same period in 2024, surpassing expectations of $107.36 million. The company also reported an earnings per share of -$0.12, which was better than the anticipated -$0.33. Following these results, Mirum Pharmaceuticals raised its 2025 revenue guidance to a range of $490 million to $510 million, indicating a projected 48% year-over-year growth at the midpoint. In light of these developments, H.C. Wainwright increased its price target for the company to $80, maintaining a Buy rating. Similarly, JMP Securities raised its price target to $81, with a Market Outperform rating, citing strong sales of Livmarli and bile acids. These updates reflect the company’s positive financial trajectory and analyst confidence in its future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.